Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.

Ruben P.A Van Eijk,Leonard H Van Den Berg,Dimitris Rizopoulos,Stavros Nikolakopoulos,Marinus J.C Eijkemans

doi:10.2147/clep.s153196

Ruben P.A Van Eijk, Leonard H Van Den Berg + Show 3 more

Open Access

https://doi.org/10.2147/clep.s153196

Copy DOI

Abstract

ObjectiveAmyotrophic lateral sclerosis (ALS) clinical trials based on single end points only partially capture the full treatment effect when both function and mortality are affected, and may falsely dismiss efficacious drugs as futile. We aimed to investigate the statistical properties of several strategies for the simultaneous analysis of function and mortality in ALS clinical trials.MethodsBased on the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we simulated longitudinal patterns of functional decline, defined by the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) and conditional survival time. Different treatment scenarios with varying effect sizes were simulated with follow-up ranging from 12 to 18 months. We considered the following analytical strategies: 1) Cox model; 2) linear mixed effects (LME) model; 3) omnibus test based on Cox and LME models; 4) composite time-to-6-point decrease or death; 5) combined assessment of function and survival (CAFS); and 6) test based on joint modeling framework. For each analytical strategy, we calculated the empirical power and sample size.ResultsBoth Cox and LME models have increased false-negative rates when treatment exclusively affects either function or survival. The joint model has superior power compared to other strategies. The composite end point increases false-negative rates among all treatment scenarios. To detect a 15% reduction in ALSFRS-R decline and 34% decline in hazard with 80% power after 18 months, the Cox model requires 524 patients, the LME model 794 patients, the omnibus test 526 patients, the composite end point 1,274 patients, the CAFS 576 patients and the joint model 464 patients.ConclusionJoint models have superior statistical power to analyze simultaneous effects on survival and function and may circumvent pitfalls encountered by other end points. Optimizing trial end points is essential, as selecting suboptimal outcomes may disguise important treatment clues.

Highlights

Amyotrophic lateral sclerosis (ALS) is an incurable, rapidly progressive, neurodegenerative disease
We considered the following analytical strategies, which are discussed later: 1) combined assessment of function and survival (CAFS); 2) Cox model based on the composite end point time-to-6 point decrease on ALSFRS-R or death; 3) omnibus test based on the joint model and 4) omnibus test based on the Cox model and linear mixed effects (LME) model
Baseline characteristics of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) cohort are given in Table 2 and are comparable with other large trial populations.[11,12]